Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

Documenti analoghi

• Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
  di: De Rycke, L, et al.
  Pubblicazione: (2005)
• Usefulness of anti-cyclic citrullinate peptide antibody determination in synovial fluid analysis of patients with rheumatoid arthritis
  di: G. Valesini, et al.
  Pubblicazione: (2011-09-01)
• Anti‐cyclic citrullinated peptide positivity in non‐rheumatoid arthritis disease samples: citrulline‐dependent or not?
  di: Vannini, A, et al.
  Pubblicazione: (2007)
• The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies
  di: van Damme, N, et al.
  Pubblicazione: (2002)
• The effect of etanercept on anti‐cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis
  di: Chen, H A, et al.
  Pubblicazione: (2006)